BioXcel Therapeutics Inc (BTAI) - שולי הרווח הגולמי

BTAI (BioXcel Therapeutics Corp) - סמל מסחרי של החברה

Stable raw material supplies ensure the operational reliability of BioXcel Therapeutics. The gross profit margin reflects cost dynamics, where the value of 22.80 represents the most recent figure. Growth is driven by the expansion of the drug Igalmi and AI technologies, although high expenses and regulatory risks threaten the company's financial stability.

BTAI: שולי רווח גולמי BioXcel Therapeutics, Inc. 04.07.2022 - 19.09.2026

פילוחי מדדים מקיפים ואנליטיקה עבור BioXcel Therapeutics, Inc. (BTAI)

- מחיר שוק ויעדי מחיר של אנליסטים:
הערכת שווי פונדמנטלית:BTAI, BioXcel Therapeutics, Inc.
מוצר ממותג של bioxceltherapeutics.com

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, determining direct production efficiency and internal profitability potential. For BioXcel Therapeutics (BTAI), this indicator reflects the economic return from applying AI in drug repositioning, allowing for an assessment of the therapy's commercial viability through the stability of the gross margin.